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Abstract
A hallmark of diseases of protein conformation and aging is the appearance of protein aggregates associated with cellular
toxicity. We posit that the functional properties of the proteostasis network (PN) protect the proteome from misfolding and
combat the proteotoxic events leading to cellular pathology. In this study, we have identified new components of the
proteostasis network that can suppress aggregation and proteotoxicity, by performing RNA interference (RNAi) genetic
screens for multiple unrelated conformationally challenged cytoplasmic proteins expressed in Caenorhabditis elegans.W e
identified 88 suppressors of polyglutamine (polyQ) aggregation, of which 63 modifiers also suppressed aggregation of
mutant SOD1
G93A. Of these, only 23 gene-modifiers suppressed aggregation and restored animal motility, revealing that
aggregation and toxicity can be genetically uncoupled. Nine of these modifiers were shown to be effective in restoring the
folding and function of multiple endogenous temperature-sensitive (TS) mutant proteins, of which five improved folding in
a HSF-1–dependent manner, by inducing cytoplasmic chaperones. This triage screening strategy also identified a novel set
of PN regulatory components that, by altering metabolic and RNA processing functions, establish alternate cellular
environments not generally dependent on stress response activation and that are broadly protective against misfolded and
aggregation-prone proteins.
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Introduction
Protein misfolding is an intrinsic aspect of protein biogenesis
that, under optimal conditions, is kept in check by the properties of
the proteostasis network (PN), and upon stress, aging, and
expression of aggregation-prone proteins causes cellular dysfunc-
tion that places the organism at risk for diseases of protein
conformation. These are common and prominent features in
Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic
Lateral Sclerosis (ALS), polyglutamine disorders such as Hunting-
ton’s disease (HD), muscular dystrophies, metabolic disorders, and
certain cancers [1–5]. Each disease is associated with its own
characteristic set of aggregation-prone proteins that differ in
sequence, function and expression patterns. Nevertheless, protein
misfolding and aggregation have similar consequences to the cell
with deleterious consequences on gene expression, protein
synthesis, folding, trafficking, clearance, and cell signaling.
The PN of molecular pathways coordinates protein synthesis,
folding, trafficking and clearance [6–8] and determines the fate of
proteins that do not acquire a native conformation. The chronic
expression of aggregation-prone proteins, as occursin conformational
disorders, not only affects the function of proteins harboring
mutations, but also challenges the stability of the PN, leading to the
amplification of protein damage and persistent proteotoxicity [4,9–
12]. While protein aggregates and inclusions represent a prominent
feature of many human diseases, it remains unanswered whether a
cell responds identically to different protein aggregates. Elucidating
the mechanism(s) by which misfolded proteins, oligomeric species,
and/or aggregates interfere with cellular function represents a
prominent challenge, given the complexity of the aggregation
process, and the large number of cellular processes affected as
proteostasis decline is propagated across tissues [6,9,13,14]. Many
studieshaveindicatedthatlargeinclusionscorrelatepoorlywithonset
and severity of neurodegeneration and support a role for the soluble
oligomeric species in toxicity [13–19]. Although intermediate species
formed by distinct proteins have been suggested to display common
structural motifs, it has been difficult to evaluate the contribution of
different types of oligomers to toxicity [20]. Furthermore, despite the
common theme of protein aggregation, growing evidence suggests
that the cause of toxicity for each disease may, in part, be specific to
the subset of molecular processes affected by the aggregated protein
[21].
An alternative approach to understanding the origin of toxicity
in each disease is to identify genetic modifiers that suppress
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misfolded proteins by enhancing global folding capacity [22].
Multiple in vitro, cell-based, and animal model systems have been
developed to investigate the molecular events underlying aggre-
gation-driven toxicity and identify modifiers of disease phenotypes
[23–31]. While mammalian model systems are notoriously
challenging to perform genome-wide screens due to the differences
in genetic background and environment, screens performed in
Saccharomyces cerevisiae, Caenorhabditis elegans and Drosophila melanoga-
ster have identified processes that maintain proteome stability,
promote folding and clearance. These include among others,
molecular chaperones, proteasome subunits, components of the
autophagy machinery, and the stress-induced transcriptional
regulators DAF-16/FOXO and HSF-1 [32–39].
Here, we established a screening strategy in C. elegans to identify
novel genetic modifiers of proteostasis that reshape the network to
increase the cellular capacity for folding, prevent protein
aggregation and suppress toxicity. Our approach was to identify
components of the PN, that when down-regulated, enhance the
functional properties of the PN to restore folding of the various
folding sensors employed in the screen. This approach was
designed to complement our previous efforts to identify enhancers
of misfolding by screening for genes that when down-regulated
caused the premature appearance of protein aggregates [35]. We
identified 63 genetic modifiers that suppressed both polyQ and
mutant SOD1 aggregation in muscle cells, of which 23 also
suppressed associated toxicity. Of these, 9 modifiers systematically
reduced the misfolding phenotypes of endogenous temperature-
sensitive proteins. These modifiers were then characterized for
dependence on HSF-1 activation and expression of cytosolic
chaperones to enhance folding. This study introduces new
proteostasis modifiers with a global effect on the stability of the
muscle cell proteome, with likely broader relevance for confor-
mational disorders.
Results
Screening Strategy for Genetic Modifiers of Protein
Aggregation
We sought to determine whether modifier genes identified in a
genome-wide RNAi screen for suppression of polyQ aggregation
and toxicity in C. elegans would be efficacious on other disease-
associated aggregation-prone proteins and endogenous metastable
proteins. With this strategy, we tested the hypothesis of conserved
modifier genes and pathways within the PN for protein misfolding
and aggregation.
We initiated the screening strategy with a genome-wide RNAi
screen to identify genes in C. elegans that, when knocked down,
suppress aggregation of expanded polyQ::YFP fusion proteins
expressed in body wall muscle (BWM) cells [26]. For this screen,
animals expressing Q35 were used, as this is a threshold length for
polyQ that exhibits adult onset protein aggregation and toxicity
[26]. This screen was accomplished using a semi-robotic assay
developed for feeding RNAi bacteria [40] to larval 1 (L1, day 1)
stage Q35 animals [35]. During early development, Q35 protein is
soluble in muscle cells until animals reach day 3 of age, when
aggregation is first detected, and thereafter aggregation and
toxicity increase with aging (Figure S1B, S1D) [26,35]. Therefore,
we selected day 6, corresponding to three days after the onset of
Q35 aggregation (Figure S1B), to perform the RNAi screen to
identify gene knockdowns that led to suppression of polyQ foci,
relative to the empty vector (EV) control. RNAi against yfp was
used as a control for the efficiency of RNAi gene-knockdown
(Figure 1A: VIII, XVI, XXIV; Figure 1C). The screen was highly
robust and identified 151 genetic modifiers that suppressed Q35
aggregation (Figure 1A, Table S1). Of these modifier genes, 91
exhibited a strong suppressor effect on aggregation by reducing the
number of Q35 foci by 60 to 80% in $75% of the RNAi-treated
animals (Table S1, Figure 1C). The remaining 60 modifiers gave
more variable results and were less effective as suppressors (i.e.
observed in ,50% of the RNAi-treated animals with ,50%
reduction in foci; Table S1).
We next used a counter-screen with animals expressing soluble
Q24, as these animals do not exhibit aggregation or toxicity [26],
to control for phenotypic changes caused by RNAi that are not
related to aggregation, such as changes in YFP fluorescence, body
morphology and size, egg-laying and sterility (Table S1). We
observed that none of the Q35 aggregation modifiers had any
effect on Q24 protein (Figure 1B), suggesting that the RNAi
suppressor effect was not due to transgene silencing. The modifiers
that did not meet these criteria or had deleterious consequences on
animal development and viability were not studied further.
Moreover, to assess whether suppression of aggregation was due
to changes in polyQ expression, we examined mRNA and steady-
state protein levels for a representative group of modifiers. We
quantified the levels of q35::yfp mRNA by rt-PCR (Figure S2) and
the levels of Q35::YFP protein by SDS-PAGE and western blot
analysis (Figure 2A). The results show that, for the RNAi modifiers
tested, suppression of aggregation occurred without affecting the
polyQ mRNA or protein levels.
To obtain evidence that the suppression of visible Q35
aggregates corresponds to the appearance of soluble Q35 protein
(Figure 1A), we used the dynamic imaging method of Fluorescence
Recovery After Photobleaching (FRAP). Inclusion-localized Q35
corresponds to an immobile state with very limited fluorescence
recovery following photobleaching (Figure 2B and 2C: Q35
control) [23,35], whereas the fluorescence of diffuse-looking Q35
in animals fed with modifier RNAi recovered immediately,
consistent with a diffuse and soluble state analogous to soluble
Q24 (Figure 2B hmg-3 and Figure 2C). These results provide
biophysical evidence for Q35 solubility identified by the visual
screening. We further examined the biochemical properties of
Q35 in total protein extracts, for a representative group of
modifiers. We found that the amount of aggregated polyQ protein
detected using native PAGE analysis was reduced, and that the
levels of soluble and diffuse species were increased (Figure 2D).
Author Summary
A common characteristic of protein conformational
diseases is the appearance of protein aggregates associ-
ated with late-onset symptoms. Here, we have taken an
unbiased genetic approach to test the hypothesis that
protein aggregation and toxicity are co-linked genetic
traits that are regulated by a common proteostasis
network. To address this, we took advantage of the
tractable genetic model Caenorhabditis elegans expressing
expanded polyglutamines (polyQ) and performed a
genome-wide RNA interference (RNAi) screen to identify
genes that altered the proteostasis environment and
suppressed aggregation and toxicity. These modifiers were
subsequently tested on animals expressing mutant SOD1
and on animals expressing endogenous proteins with
temperature-sensitive mutations. This screening triage
resulted in the identification of nine genes with effects
on protein folding, corresponding to new proteostasis
pathways involved in metabolism and RNA processing
functions.
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specific modifier genes suppressed polyQ aggregation by main-
taining the protein in a mobile soluble state.
The identity of the RNAi-targeted genes was verified by
sequencing of the dsRNA plasmids, followed by Blast analysis in
NCBI and Wormbase databases. The Q35 aggregation modifier
genes are 88% conserved, with predicted human orthologs, and
can be grouped into seven functional categories of cell cycle, DNA
synthesis and repair; RNA synthesis and processing; protein
synthesis; protein folding and turnover; cell structure and protein
trafficking; signaling; and energy and metabolism (Table S1,
Figure S3A, S3B). The fraction of modifiers represented in each
functional class is significantly distinct from their representation in
the C. elegans RNAi library (Figure S3A, S3B) [41], indicating
enrichment for cellular processes important for proteostasis.
We next asked whether the Q35 modifiers were effective on
another polyQ model as a way to distinguish the most robust
polyQ aggregation suppressors. This was done by screening a
transgenic line expressing Q37::YFP. These animals exhibit a
more rapid onset of aggregation relative to Q35 animals, between
day 2 and 3 of age, together with a more rapid decline in motility
(Figure S1A, S1B, S1D). These phenotypes are dependent solely
upon the CAG-repeat length as the levels of Q35 and Q37 are
identical (Figure S1C). Q37 animals were fed RNAi from L1 stage
(day 1) and aggregation was examined on day 5, corresponding to
three days post-aggregation onset (Figure 3A, 3B). Of the initial
151 modifiers of Q35 aggregation, only 88 of these also suppressed
Q37 aggregation, of which 81 corresponded to the strongest Q35
suppressors (Table S1). We designated the set of common
modifiers of Q35 and Q37 aggregation as Class A strong modifiers
(Table 1), and the remaining 63 genes as Class B weak modifiers
(Figure 3C).
Identification of Common Modifiers of PolyQ and Mutant
SOD1 Aggregation
We next tested whether the genetic modifiers of polyQ
aggregation would be effective on yet another model that expresses
the mutant human SOD1
G93A. This model shows aggregation
Figure 1. Genome-wide RNAi screen for suppression of Q35 aggregation. (A) Q35 animals (6 days old) show suppression of aggregation
relative to EV control. Representative modifier genes: cdk-1 (cyclin-dependent kinase); let-607 (CREB/ATF transcription factor); cyn-11 (cyclophilin); klp-
15 (kinesin-like protein); sri-57 (serpentine receptor) and F59C6.5 (NADH-ubiquinone oxidoreductase). yfp-RNAi is the control for RNAi efficiency.
Panels IX–XXIV are higher magnification images of the boxed areas in I–VIII. Scale bars: 0.1 mm (I–XVI), 0.05 mm (XVII–XXIV)]. (B) Animals expressing
soluble Q24 were used as a control for RNAi phenotypes dissociated from aggregation (scale bar 0.1 mm). (C) Q35 aggregate count (% foci relative to
EV control) for a representative group of modifiers (6SD, n.3). Student t-test ***p,0.001 relative to control.
doi:10.1371/journal.pgen.1002438.g001
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blotting analysis of protein samples from Q35 RNAi-treated animals (6 days old), immunoblotted with anti-YFP (32 KDa) and anti-a-tubulin (55 KDa)
antibodies. Control refers to EV RNAi (I–IV). YFP/tubulin ratios were calculated from protein band intensities and are shown as an average % of the
control (6SD, from $3 biological replicates, Student t-test p.0.05). yfp-RNAi in panel II is the positive control for reduced protein levels. (B,C) FRAP
analysis confirms suppression of polyQ aggregation to a diffuse state. (B) Q35 protein was subjected to photobleaching in animals treated with
control RNAi (left) or hmg-3 RNAi (right) and fluorescence recovery was measured at the indicated time points. (C) Quantitative FRAP analysis
indicates the relative fluorescence intensity (RFI) at each time point, and it represents an average of $12 independent measurements for each RNAi (5
for the controls). The soluble Q24 control is shown in black solid line, and the Q35 foci control in black dashed line. (D) Native PAGE analysis of whole
protein extracts from 6 day old Q35 animals treated with RNAi. Q35 aggregated protein retained at the top of the gel was reduced by each of the
modifiers tested.
doi:10.1371/journal.pgen.1002438.g002
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foci that persists throughout adulthood (Figure S1E, S1F) [12]. Of
the 88 polyQ aggregation modifiers, 63 also suppressed mutant
SOD1
G93A aggregation in 5 day old animals (Figure 4A, Table
S1), without causing phenotypic changes in SOD1
wt animals (not
shown). A subset of these common aggregation suppressors were
also examined by SDS-PAGE and western blot analysis, and
shown not to reduce steady-state protein levels of SOD1
G93A
(Figure 4B). 95% of the mutant SOD
G93A suppressors belong to
the polyQ Class A modifiers (Table S1). Unlike Q35 aggregation
that is only detected in young adult animals, mutant SOD
G93A
aggregation occurs in embryos [12], and yet many Class A
modifiers were effective suppressors of SOD1 aggregation
providing additional support that Class A modifiers are robust
modifiers of protein folding. Moreover, these modifiers, that are
common to polyQ and SOD1, exhibit a similar overall distribution
into functional classes (Figure S3C) as was described for modifiers
of polyQ aggregation (Figure S3B), thus identifying new modifier
pathways that are common to protein aggregation.
We propose that these new modifiers can either suppress
aggregation directly by affecting cellular processes that mediate
aggregate formation, or indirectly by altering some aspect of the
PN that confers a protective action that increases folding. To
distinguish between these two possibilities, we employed genetic
tests to determine which modifiers reflect an improvement of the
folding environment, by reducing misfolding and associated
toxicity.
Suppression of Aggregation Can Be Uncoupled from
Toxicity
Protein aggregation is a common feature of many diseases;
however, the relationship between aggregation and cellular
toxicity remains controversial. The appearance of aggregates
and inclusions has been linked both to cellular dysgenesis and
toxicity, as well as protection from toxicity [13–19]. Therefore, we
took advantage of an unbiased genetic approach to test the
relationship between suppression of aggregation and toxicity.
Because the initial genetic screens were based solely on
aggregation phenotypes, we were able to subsequently perform
cellular toxicity assays to assess this relationship.
Relative to wt animals or animals expressing soluble polyQ
(Q24), Q35 animals exhibit muscle dysfunction resulting in a 40%
loss of motility at 6 days of age (Figure S1D) [26]. Therefore, we
quantified the motility of RNAi-treated Q35 animals as a measure
of polyQ-associated cellular toxicity, using an automated worm
tracker system analysis, validated by manual methods. As a
reference positive control for toxicity suppression, we show that
motility was restored to near wt levels by knockdown of the Q35
transgene expression with yfp-RNAi (Figure 5A). All 88 Class A
modifiers were tested for effects on the motility of Q35 animals
and wt control animals (Table S2). Because we sought to identify
improvement of motility directly associated to suppression of Q35
aggregation, we excluded any modifier that, alone, had effects on
the motility of wt animals. Of the 88 modifiers tested in wt
animals, 33 gene knockdowns (37%) affected the motility of wt
Figure 3. Common RNAi suppressors of Q35 and Q37 aggregation. (A) Counter-screen in 5 day old Q37 animals to identify the strongest
suppressors of polyQ aggregation. Panels IX–XVI show a higher magnification image of the boxed areas on I–VIII. Scale bar is 0.1 mm. (B) Q37
aggregate count (% foci relative to EV control) for a representative group of modifiers (6SD, n.3). Student t-test ***p,0.001 relative to control. (C)
Screen strategy: genome-wide screen with the threshold Q-length for aggregation Q35, and counter-screens with the soluble Q24 and the higher Q-
length Q37 strains. Class A refers to Q35 and Q37 common strong modifiers, and Class B to modifiers only affecting Q35.
doi:10.1371/journal.pgen.1002438.g003
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the remaining 55 modifiers, 42% improved the motility of Q35
animals to wt levels, 36% had no effect, and 22% enhanced the
toxicity of Q35 (Figure 5A). These results revealed that
suppression of aggregation, as detected by visual, biophysical,
and biochemical measures, does not necessarily predict that the
physiological health of the cell will be restored. The genetic
uncoupling between aggregation and toxicity further reinforces
previous similar observations [13,14,19]. Taken together, the
toxicity in diseases of protein conformation is the outcome of a
complex series of misfolding events, involving multiple species and
aberrant interactions within the cell.
Identification of a Core PN by Screening with
Endogenous Metastable Proteins
Among the challenges with studies of protein misfolding and
aggregation have been the concerns with the physiological
imbalance associated with overexpression of heterologous proteins
in the respective model systems. To circumvent this concern, we
asked whether the PN modifiers that suppressed polyQ and
mutant SOD1 aggregation (Figure 5C) would also restore the
folding of endogenous metastable proteins harboring temperature
sensitive (TS) mutations. TS-mutations represent an important
class of highly sensitive folding sensors that are expressed at
normal endogenous levels and have quantifiable phenotypes when
properly folded at the permissive condition or misfolded at the
restrictive temperature [10,42,43]. This strategy was also used to
distinguish between modifiers that directly perturb and suppress
the formation of protein aggregates, from the modifiers that
reshape the PN to improve the protein-folding environment.
We examined the properties of four TS mutant proteins
corresponding to the paramyosin ortholog UNC-15, the base-
ment-membrane protein perlecan UNC-52, the myosin-assembly
protein UNC-45, and the myosin heavy chain UNC-54 [10]. At the
permissive temperature (15uC), each of these TS-proteins is known
to be fully functional and animals harboring these mutants exhibit a
wtphenotype,whereasatthe restrictivetemperature(23uCor25 uC)
these TS-proteins misfold and cause muscle dysfunction that can be
measured as slow movement and paralysis (UNC-15, UNC-54,
Figure 6A, 6C), egg-laying defects leading to swelling and paralysis
(UNC-45, Figure 6B), and stiff-paralysis (UNC-52, Figure 6D) (see
Materials and Methods) [10,42,44]. These phenotypes are specific
to animals expressing the TS mutations, and are not observed in wt
animals. We tested all 23 RNAi modifiers that suppressed both Q35
aggregation and toxicity (Figure 5C), on each of the TS strains, and
found that a total of nine modifiers reduced the number of animals
displaying TS phenotypes by 40% to 90% at 23uC, a slightly lower
restrictive temperature at which the efficiency of the RNAi protocol
was maintained (Figure 6A–6D, Table 2). These results suggest that
while protein misfolding is common to all three classes of folding
sensors (polyQ, mutant SOD1, and TS-mutant proteins), the
cellular environment and the PN are influenced differentially by the
Table 1. Overview of the modifiers that suppress Q35 and Q37 (Class A) aggregation in C. elegans BWM cells.
Process(# Genes) Molecular Function (# Genes) Gene
Cell Cycle DNA Synthesis
and Replication (8)
Cell Cycle (1) cdk-1
DNA recombination (2) fbxb-11; fbxb-17
Meiosis (1) F46F11.9
Replication (4) mcm-2; rnr-2; rpa-1; ruvb-1
Cell structure and Protein
transport (6)
Cellular matrix, cuticle (4) ppn-1; col-61; col-69; viln-1
Vesicle trafficking (2) klp-15; nex-1
Energy and Metabolism (17) Metabolism (9) C50D2.2; R03D7.1; C47F8.4; C54C8.5; D2030.1; elo-2;
W06H3.3; F43G9.1; T22B11.5
Electron transport chain (5) C34B2.8; F59C6.5; ucr-2.3; cyp-13B2; cyp-33D1
Ion transport (2) B0281.5; catp-4
Mitochondrial function (1) F43E2.7
Protein Folding and transport (7) Chaperone (6) F08H9.3; cyn-11; cyn-12; C30C11.4; dnj-22; phb-2
Protein glycosylation (1) tag-335
Protein Synthesis (10) Mitochondrial ribosome (3) C26E6.6; F33D4.5; mrpl-41
Ribosomal protein (3) rpl-2; rpl-35; rps-21
Translation (4) krs-1; F17C11.9; H19N07.1; R05D11.4
RNA Synthesis and Processing (13) Nucleosome binding (2) hmg-3; hmg-4
Ribosome biogenesis (1) C15H11.9
RNA processing, splicing (5) F13H8.2; fib-1; let-716; ZK430.7; Y110A7A.8
Transcription (5) C55A6.9; K03F8.1; fkh-6; gei-11; let-607
Signaling (10) Receptor protein (6) dao-5; xpo-1; sri-57; sri-78; srz-53; T11F1.6
Transduction (4) clec-19; pdl-1; rgl-1; W03B1.9
Unknown (17) Unknown (17) C23G10.10; C45G3.4; F14B8.2; F26E4.2; F47F2.3; K02E7.11; ptr-19; R05D7.2;
ril-1; smu-1; T04D3.5; vab-19; F53F10.1; W03B1.5; Y51H7BR.3; fbxa-76; F54C4.3
doi:10.1371/journal.pgen.1002438.t001
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that these final nine modifiers (Figure 7A) are core PN modulators
that confer improvement of cellular folding capacity in C. elegans
muscle cells.
Folding Enhancement by Activation of the Heat Shock
Response
Upstream of the core components of the PN is the master
cytosolic stress-responsive pathway that leads to HSF-1 activation
and expression of molecular chaperones for stability of the
proteome. To examine whether the nine PN modifiers
(Figure 7A) lead to HSF-1 activation as a general mechanism for
proteostasis improvement, we introduced a hypomorphic muta-
tion of hsf-1(sy441) into the background of the polyQ strain Q37
and knocked-down each modifier gene (Figure 7B). Our results
show that: suppression of aggregation by ucr-2.3, gei-11 and
C45G3.4 was completely dependent on HSF-1; whereas
T22D11.5, ZK430.7, Y110A7A.8 and R05D11.4 exhibited a weaker
dependence on HSF-1; and F43G9.1 and let-607 were independent
of HSF-1. We next examined whether chaperone gene expression
was affected downstream of the nine PN modifiers, by monitoring
the expression of Hsp70 (C12C8.1, F44E5.4) and small Hsp (hsp-
16.1), upon knockdown of each genetic modifier (Figure 7C). We
show that five of nine PN modifiers induced expression of
cytoplasmic chaperones. Knockdown of let-607 (ER-UPR, Table 2)
had the strongest effect, suggesting an important regulatory
crosstalk between cytoplasmic and ER stress response pathways.
Knockdown of the TCA cycle component T22B11.5 led to
upregulation of chaperones and establishes a link between folding
and metabolic state, whereas knockdown of gei-11 (putative
negative regulator of cholinergic signal, Table 2) induction of hsp
suggests an effect of cholinergic signaling on muscle homeostasis
(Figure 7C). Reduction of R05D11.4 (translation) leading to
induction of hsp-70 was consistent with an effect of protein
synthesis on folding machinery. For the remaining four PN
modifiers, knockdown of ZK430.7 (RNA processing) had a modest
effect on hsp expression, while knockdown of Y110A7A.8 (splicing),
ucr-2.3 (ETC) and F43G9.1 (TCA cycle) had no effects on hsp levels
(Figure 7C, Table 2). This suggests that proteostasis was restored
through other pathways involving reduced metabolism and energy
production. Taken together, these results demonstrate that
improvement of the cellular folding environment by these novel
proteostasis modulators is not simply a consequence of a
generalized induction of the heat shock response and molecular
chaperones but also involves other PN pathways, not previously
linked to proteome surveillance.
Discussion
Genetic screens have provided invaluable insights into biolog-
ical processes, and have the advantage of being unbiased and
Figure 4. PolyQ aggregation modifiers tested in the mutant SOD1
G93A model. (A) Representative RNAi suppressors of SOD1
G93A
aggregation: ucr-2.3 (ubiquinol cytochrome c reductase); F43G9.1 (isocitrate dehydrogenase); ZK430.7 (sof1-like rRNA processing protein); gei-11 (GEX-
3-interacting protein, Myb transcription factor); let-607 (CREB/ATF transcription factor); R05D7.2 (unknown) and yfp RNAi control. Higher magnification
images (IX–XVI) of the boxed areas (I–VIII) show reduced number of SOD1
G93A foci in animals treated with RNAi, relative to the EV control. Scale bar is
0.1 mm. (B) SDS-PAGE and western blot analysis of protein samples from SOD1
G93A RNAi-treated animals (5 days old), immunoblotted with anti-YFP
(32 KDa) and anti-a-tubulin (55 KDa) antibodies. Control refers to EV RNAi. YFP/tubulin ratios (bottom) were calculated from protein band intensities
and are shown as an average % of the control (I, II) 6SD, from $3 biological replicates (Student t-test p.0.05). yfp-RNAi (II) is the positive control for
reduced protein levels.
doi:10.1371/journal.pgen.1002438.g004
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genetic strategy to explore how the proteostasis network can be
genetically modulated to increase cellular protection against the
toxicity of protein aggregation (Figure 7A). This strategy benefitted
from certain advantages of C. elegans as a metazoan model for the
expression of conformationally challenged proteins and the ability
to screen the genome for modifiers that suppress both aggregation
and toxicity by gene knockdown. This complements the candidate
gene approaches that led to the identification of molecular
chaperones, ubiquitin proteasome, autophagy, and the upstream
stress response signaling pathways. The use of a screening triage
approach (Figure 7A) revealed that genetic modifiers that suppress
aggregation of polyQ are also effective with mutant SOD1, and
revealed the identity of candidates of a core PN. However, only a
subset of these suppressors of aggregation also suppressed cellular
toxicity, a result that is consistent with the genetic uncoupling
between aggregation and toxicity observed in various disease
models [13–19]. This screen ultimately provided a filter that led to
identification of a final set of nine core muscle PN modifier genes
(Table 2), not previously shown to be directly involved in protein
homeostasis and the restoration of folding in both animal models
of protein aggregation and endogenous metastable proteins.
New Genetic Modulators of Protein Aggregation
The genome-wide screen for suppression of polyQ aggregation
identified a collection of modifier genes from distinct cellular
functional classes (Table S1, Figure S3B). Modifiers in the category
cell structure and protein transport, include cytoskeleton components
(filamin) and matrix proteins (ppn-1, mua-3, gon-1), supporting
observations that aggregation can be affected by disturbing the
integrity of cell structure [10]. Other genes in this group encode
motor proteins involved in vesicular trafficking (klp-15, nex-1),
consistent with a role for protein movement and transport in
aggregation. Cell growth and replication modifiers are involved in
Figure 5. Suppression of polyQ aggregation and toxicity are genetically uncoupled. (A) Motility measurements of Q35 (black) and wt
(grey) animals treated with aggregation suppressor RNAi. Motility is measured in body-length per second relative to wt motility in EV control (%
BLPS6SEM). Shown here are the modifiers that did not affect wt motility, grouped in three classes that: enhance Q35 motility defect (Student t-test
**p,0.001); cause no change (Student t-test p$0.05); or suppress Q35 motility defect (Student t-test **p,0.01) relative to Q35 control. Statistical
significance between classes calculated by 1-way ANOVA ***p,0.0001; and t-test ***p,0.001. (B) Aggregation modifiers that caused a deleterious
effect on wt motility (% BLPS6SEM, relative to EV control). Student t-test ***p,0.001 relative to control. (C) Screening triage for modifier suppressors
of protein aggregation and toxicity.
doi:10.1371/journal.pgen.1002438.g005
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DNA replication and recombination (transposases), with a likely
general effect on growth rate and development. Energy and
metabolism modifier genes are involved in energy production and
mitochondrial electron transport chain (ETC) function. Restric-
tion in energy levels not only affects overall protein biogenesis, as it
is a highly ATP-dependent process, but also, metabolic enzymes
can influence protein folding in the cell by altering the levels of
organic/inorganic solutes with effects in polypeptide chain
solvation [6]. Notably, reduced ATP synthesis, ETC activity or
mitochondrial function have been shown to enhance lifespan,
possibly by delaying age-dependent decline in protein folding
capacity and by upregulation of stress-response pathways that
promote proteostasis and survival [45–48]. Gene expression and protein
synthesis related modifiers function in RNA metabolism, ribosome
biogenesis, and protein synthesis. This is consistent with reduced
translation increasing C. elegans lifespan, perhaps by activating a
physiological state with increased stress resistance and folding
capacities [49–51]. Post-translational control modifier genes are
involved in chaperone-assisted folding, such as HSP70 superfamily
members, DNAJ co-chaperones and cyclophilins, and post-
translation modifying enzymes such as SUMO and E3-ubiquitin
ligases. The role of chaperones on protein solubility, misfolding
and aggregation has been well established [52,53], and an
imbalance in certain co-chaperones has been suggested to alter
chaperone activity in the cell and folding [54]. Signaling RNAi-
targeted genes included nuclear hormone receptors, G-protein-
coupled receptors, C-type lectins (endocytic receptors), or calcium
export and channel-transport activity. These regulators affect
reproduction, growth, morphogenesis (development), and locomo-
tion by altering signaling pathways involved in neuronal and
muscle function.
Genetic Screens for Enhancer and Suppressor Modifiers
of PolyQ Aggregation
Information retrieved from comparative analysis of genetic
screens of different misfolded proteins can provide important
insights to identify both common and protein-specific pathways for
conformational disorders (Table S3). Highly relevant to this point
is our ability to compare the modifier genes identified in this study
with a previous complementary screen using the same threshold
Q-length properties of the Q35 model to identify genes that when
knocked-down by RNAi led to premature onset of polyQ
aggregation [35]. Together, these genome-wide screens identified
Figure 6. Aggregation modifiers that rescue the folding of endogenous TS mutant proteins. Modifiers of aggregation and toxicity were
tested on endogenous muscle TS mutant proteins. 15uC is the permissive temperature, 25uC is the restrictive temperature and 23uC is the
temperature used for RNAi. Misfolding of TS mutant proteins was assessed by measuring the % of animals displaying the associated muscle
dysfunction phenotype: (A) unc-15(e1402) (paramyosin), uncoordinated/slow movement; (B) unc-45(e286) (myosin assembly protein), egg laying and
paralysis defect; (C) unc-54(e1157) (myosin), slow movement/paralysis; (D) unc-52(e669su250) (perlecan), stiff paralysis (6SD, n.3, Student t-test
relative to 23uC control **p,0.01, ***p,0.001). Statistical comparison using 1-way ANOVA ***p,0.001.
doi:10.1371/journal.pgen.1002438.g006
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and pathways, but correspond to distinct genes within these
pathways. Specific modifier genes may interfere with the misfolded
species at different stages of the aggregation process with opposite
outcomes, consistent with the functional properties of a network,
where different components within a process can shift the
equilibrium in opposing directions to alter the stability of the
proteome, to intensify or suppress the polyQ phenotype.
While it might seem counter-intuitive that molecular chaperones
could suppress polyQ aggregation when knocked-down, this is
consistent with observations that proteome stability can be
enhanced or suppressed by changing the composition of the cellular
chaperome [52–55]. For example, reducing the expression of cyn-11
and cyn-12 (cyclophilin D isoforms) and dnj-5, that function
primarily as co-chaperones to regulate Hsp70 and Hsp90 activities
[56], promotes a polyQ soluble state. These co-chaperones could
function as negative regulators of chaperone function, and their
down-regulation results in enhanced chaperone activities leading to
suppression of misfolding [52,57,58]. This would be consistent with
evidence that Hsp70 folding activity is negatively regulated by co-
chaperones and co-factors such as CHIP [59] and BAG-1 [60].
Therefore,enhancement of foldingcanbe achieved by both positive
and negative regulation of chaperones or by a compensatory
response that up-regulates other chaperones.
Another functional class common to both Q35 screens is the
protein trafficking and cell matrix. Suppression of aggregation by
knockdown of cell cytoskeleton proteins, such as intermediate
filaments (MUA-3 and MUA-6) and filamin, is supported by
experimental evidence that the dynamics of aggregation rely in
part on translocation of proteins into inclusions. For example, the
active transport of Htt-exon1 along microtubules has been shown
to be required for inclusion body formation [61]. In contrast,
premature aggregation was observed when the expression of
vesicle proteins involved in protein trafficking was knocked-down
[35], including TFG-1 COP-II complex, APT-3 and APT-1, and
cell membrane assembly proteins (SNAP-25). Interference with
these processes can disturb essential steps of the folding and
secretory pathways, increase the load of misfolded proteins in the
cell and lead to premature polyQ aggregation.
Suppression of PolyQ Aggregation and Toxicity Can Be
Uncoupled
An important observation from these studies is that the Class A
PN modifiers (Figure 3C, Table 1) were highly effective to suppress
polyQ aggregation, and yet only 42% of these modifiers also
reduced toxicity, with approximately equal numbers of modifier
genes with either no effect on toxicity or even enhancing toxicity
(Figure 5A). These results provide independent evidence that
suppression of aggregation alone does not predict that the
physiological health of the cell will be restored. From a
mechanistic perspective, it is increasingly clear that a series of
events are associated with the conversion of the nascent polyQ
protein into different oligomeric states, immobile aggregate species
and inclusion bodies [62–65]. We conclude that the genetic
suppression of aggregation can occur via a wide range of
mechanisms that are dissociated from the effect on toxicity,
Table 2. Core modulators of protein homeostasis in C. elegans BWM cells.
Gene/
Cosmid Class Molecular function Human ortholog Expression TS Direct Interactors (STRING 9.0)
ucr-2.3 EM Ubiquinol cytochrome
c reductase, complex
III ETC
UQCRC2, Cytochrome
b-c1 complex III
Ubiquitous,
mitochondrial
3/4 ETC complex III subunits: cyc-1, isp-1, ucr-2.2,
T27E9.2, F45H10.2, T02H6.11, R07E4.3.
F57B10.14 (unknown).
F43G9.1 EM Isocitrate dehydrogenase
a-subunit, TCA cycle
IDH3A, Isocitrate
dehydrogenase,
a-subunit
Ubiquitous,
mitochondrial
2/4 Aconitase (aco-1, aco-2), ATP synthase (atp-2),
Isocitrate dehydrogenase subunits (C37E2.1,
idh-1, idh-2, C30F12.7, F35G12.2) OGDH
subunits (T22B11.5, ZK836.2)
T22B11.5 EM 2-oxoglutarate
dehydrogenase, E1
subunit, TCA cycle
OGDHL, 2-oxoglutarate
dehydrogenase E1
Ubiquitous,
mitochondrial
4/4 OGDH subunit (W02F12.5, ZK836.2), Isocitrate
dehydrogenase subunits(idh-1, idh-2,
C37E2.1,C30F12.7, F43G9.1), LLC1.3, glutaryl-
CoA-dehydrogenase (F54D5.7), Malonyl-CoA
decarboxylase (F35G12.1)
ZK430.7 RSP Sof1-like rRNA
processing protein
WDSOF1, WD repeat
and SOF domain-
containing protein 1
Muscle enriched,
nucleus
4/4 rRNA processing (fib-1, C05C8.2), ribosome
(C48B6.2, nep-1, F13H8.2), acyltransferase
(F55A12.8), tryptophan protein 2 (F55F8.3),
Bystin (byn-1), nucleolar protein (nol-10)
Y110A7A.8 RSP Putative mRNA
splicing factor PRP31
PRPF31,
U4/U6-SNRP
Oogenesis
enriched
4/4 RNA processing and splicing: prp-8, M28.5,
Y59A8B.6, prp-4, rpl-3, ism-6. M03C11.4
(unknown)
gei-11 RSP GEX-interacting
protein 11 MYB-family
SNAPC4, MYBL2,
MYB, MYBL1
Nucleus 4/4 Acetylcholine receptor subunit (unc-29),
tissue morphogenesis (gex-3)
let-607 RSP CREB-ATF
transcription
factor
CREB3L3/L4, CREBH
transcription factor
BWM, neurons,
vulva, pharynx,
spermatheca, ER,
nucleus
4/4 -
R05D11.4 PS ATP-dependent RNA
helicase, translation
DDX52, ATP-dependent
RNA helicase
Intestine, muscle,
cytoplasm
1/4 -
C45G3.4 U Unknown Unknown - 1/4 -
Key: EM (energy and metabolism); RSP (RNA synthesis and processing); PS (protein synthesis); U (unknown); TS (temperature sensitive mutant proteins showing
suppression of phenotype/total tested).
doi:10.1371/journal.pgen.1002438.t002
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aggregation process could in some cases enhance the formation of
‘‘toxic oligomeric species’’ [13–19,66–68]. Moreover, each
modifier gene is certain to function within its own network of
interacting partners (Table 2), revealing an expanding network
through which each modifier can suppress aggregation, but with
differential effects on toxicity depending on the affected cellular
function. The demonstration that protein aggregates are uncou-
pled from cellular toxicity has implications for the understanding
of the PN and for development of therapeutics.
Triage Screening Method for Identification of Core
Modulators of BWM Proteostasis
We took advantage of C. elegans models of protein aggregation-
toxicity in addition to folding sensor strains harboring TS
mutations in endogenous proteins to identify a core group of
modulators that improve folding in muscle cells (Figure 7A). Our
results highlight important aspects of the PN, relevant for both
‘gain-of-toxic function’ by aggregation-prone proteins, and ‘loss-
of-function’-derived toxicity due to protein misfolding. The nine
PN modifiers that remained at the end of the screening tree
function in the mitochondrial respiratory chain and TCA cycle,
that regulate metabolism, energy balance and prevention of
oxidative stress, in addition to rRNA processing and transcription,
that determine gene expression and proteome load (Table 2).
While these modifier genes, upon initial inspection, seem not to be
directly involved in folding, perturbation of their specific functions
and networks of interactions re-adjusts the PN to enhance its
capacity, as suggested by activation of the heat shock response and
chaperone expression (Figure 7B, 7C). Moreover, comparison to
other genetic screens performed in Drosophila [32,33,39], C. elegans
[34–37,69,70] and yeast [38,71] (Table S3) provides additional
insights into the regulation of the PN by these modifiers. ucr-2.3
encodes an ubiquinol-cytochrome c reductase subunit of the
mitochondrial respiratory chain, and F43G9.1 and T22B11.5
encode TCA-cycle enzymes (isocitrate dehydrogenase and 2-
oxoglutarate dehydrogenase, respectively) (Table 2). Disruption of
the respiratory chain and energy production has been suggested to
have consequences on cellular homeostasis [47,48]. Intriguingly,
knockdown of ucr-2.3 was shown to enhance the toxicity of human
Tau expressed in C. elegans neuronal cells (Table S3) [34]. This
discrepancy may be related to Tau-specific proteotoxicity, not
derived from aggregation or misfolding, but associated with
microtubule binding and disruption. F43G9.1 was also identified as
a enhancer of lifespan [70], which is consistent with a role in
proteostasis. ZK430.7 encodes an rRNA processing factor,
Y110A7A.8 is a putative mRNA splicing factor, and R05D11.4
encodes an RNA helicase required for translation (Table 2). Thus,
perturbing components of the gene expression machinery can
enhance proteostasis, likely by altering the expression load of
unstable proteins and activating stress responses to restore
proteostasis. In particular, knockdown of Y110A7A.8 activates
Figure 7. Core PN modifiers and activation of the heat shock response. (A) Screening strategy to identify genetic modifiers that enhance the
folding environment and are effective in multiple misfolding models. (B) Suppression of polyQ aggregation by the final nine modifiers dependence
on HSF-1. Aggregate quantification on RNAi-treated Q37;hsf-1(sy441) hypomorphic mutant animals relative to control (6SD). Student t-test *p,0.05;
**p,0.01; ***p,0.001 (ns, non-significant). (C) Real-time qPCR analysis of the levels of hsp (C12C8.1, F44E5.4, hsp-16.1) genes in RNAi-treated wt
animals. Data are relative to the levels of each gene in wt;EV control (6SD) from 3 biological replicates.
doi:10.1371/journal.pgen.1002438.g007
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polyQ aggregation on 3 day old animals [35], consistent with an
increase in misfolding (Table S3). However, on 6 day old animals
we show that the number of aggregates is suppressed, which
suggests a time-dependent response by the PN to enhance the
folding machinery and restore folding. gei-11 encodes a Myb-
family transcription factor proposed to regulate cholinergic
receptor function at the BWM cells [72], which affects muscle
function and homeostasis [43,73]; and let-607 encodes a CREBH
ortholog transcription factor predicted to be a component of the C.
elegans ER stress response. The role of let-607 is particularly
intriguing as it reveals a genetic crosstalk between the cytoplasmic
and ER lumen stress pathways. Knockdown of let-607 induces
chaperone expression that is not dependent upon HSF-1
(Figure 7B, 7C), suggesting that other stress responses such as
the ER unfolded protein response may be involved in the
suppression of cytosolic protein aggregation. Taken together,
these results emphasize that diverse genetic and cellular mecha-
nisms can restore cellular proteostasis beyond the traditional heat
shock response. These nine gene modifiers of BWM protein
homeostasis represent core components of the PN that evoke a
robust and effective improvement of disease-related and endog-
enous metastable protein folding. Identification of these processes
is a fundamental step towards identifying new components that
constitute the network, and the cellular and organismal mecha-
nisms by which they contribute to protein homeostasis and protect
against chronic expression of misfolded toxic proteins.
Materials and Methods
C. elegans Strains and Maintenance
Animals were maintained according to standard methods, at
20uC on nematode growth media (NGM) with OP50 E. coli [74].
The strains utilized in this work, and previously described, are the
following: wild-type (wt) Bristol strain N2; polyQ strains
Q0 AM134 (rmIs126[Punc-54::yfp]), Q24 AM138 (rmIs130
[Punc-54::q24::yfp]II), Q35 AM140 (rmIs132[Punc-54::q35::yfp]I), Q37
AM470 (rmIs225[Punc-54::q37::yfp]II) (Text S1) [26,35]; human
SOD1 strains SOD1
G93A AM265 (rmIs177[Punc-54::sod1
G93A::yfp])
and SOD1
WT AM263 (rmIs175[Punc-54::sod1
wt::yfp]) [12]; tempera-
ture sensitive (TS) mutant strains CB1402 [unc-15(e1402)],
CB1157 [unc-54(e1157)], HE250 [unc-52(e669su250)] and CB286
[unc-45(e286)] [10]. The transgenic polyQ and SOD1 strains had
been integrated by gamma-irradiation, 5 times backcrossed, and
were previously described [12,26]. The strain Q37;hsf-1(sy441)
was generated by genetic cross of the original strains AM470 and
PS3551[hsf-1(sy441)]I.
RNA Interference Screen
The genome-wide RNAi screen for suppression of aggregation
in C. elegans muscle cells was performed using the commercial
RNAi library, with bacteria expressing dsRNA for 87% of the
predicted C. elegans genes (GeneService, USA) [35,40]. A semi-
automated high throughput setup system was used, consisting of a
robotic device (Biomek FX Liquid Handler, Beckman Coulter,
USA) programmed to add bacteria and age-synchronized animals
in liquid culture to 96-well plates. RNAi bacterial cultures were
grown for approximately 8 h in LB-ampicillin 50 mg/ml (65 ml), at
37uC with continuous shaking at 315 rpm (Orbital shaker,
GeneMachines HiGro, Genomic Solutions, USA), and induced
with 0.5 mM isopropyl b-D-thiogalatoside (IPTG, Sigma) for 3 h
at 37uC. To obtain an age synchronized population of L1 larvae
(first larval state post egg hatching), Q35 gravid adults were
bleached with a NaOCl solution [250 mM NaOH and 1:4 (v/v)
dilution of commercial bleach] and the eggs hatched in M9 buffer
overnight at 20uC. Day 1 is defined as 18 h following NaOCl age-
synchronization and animals are said to be 1 day old (L1 stage). 10
to 15 animals were added to each well in the 96-well plate in a
volume of 50 ml of M9 plus [M9, 1 mg/ml cholesterol, 50 mg/ml
ampicillin, 10 mg/ml tetracycline, 0.1 mg/ml fungizone and
170 mg/ml IPTG] and incubated at 20uC with continuous shaking
at 200 rpm (Innova 4430 Incubator Shaker, New Brunswick,
USA). Animals were scored 5 days later (6 days old) for reduction
in the number of fluorescent foci using the stereomicroscope Leica
MZ16FA equipped for epifluorescence (Leica Microsystems,
Switzerland). As a negative control, animals were fed bacteria
carrying the L4440 empty vector (EV). Suppression of aggregation
was scored positive when more than 50% of the animals had a
50% or higher reduction in foci number relative to the EV control,
without loss of YFP fluorescence, changes in growth rate or
development of the animals. The candidate positive hits were re-
screened (n$3), then tested in the Q24 soluble control strain, and
counter screened in Q37 animals (5 days old) and SOD1
G93A
animals (5 days old). In Q37 and SOD1
G93A animals, suppression
of aggregation was scored positive when more than 50% of the
animals showed a reduction in foci number (.25%). RNAi was
always added on day 1. The identity of the RNAi-targeted genes
was verified by sequencing of the dsRNA plasmids, followed by
Blast analysis in the NCBI and Wormbase databases revealing
high specificity of genomic sequence targeting. Gene-knockdown
by the respective RNAi was also confirmed for a representative
group of hits by rtPCR (data not shown). For RNAi assays on
plates (for foci scoring, FRAP and motility analysis, to collect
animals for western blot and real-time qPCR, and for TS assays),
NGM media was supplemented with 100 mg/ml ampicillin, 1 mM
IPTG and 12 mg/ml tetracycline (Sigma), and seeded with
overnight (16 h) RNAi bacteria cultures, pre-induced with IPTG
(1 mM, 3 h). One day old (L1) animals (15 to 20 animals) were
transferred onto NGM-RNAi bacteria seeded plates and grown at
20uC, and at the time indicated aggregation was scored in at least
50 animals, for each condition (n=3). Aggregates were defined as
discrete, bright foci that can be distinguished from their
surrounding fluorescence by increased brightness intensity. The
detection limit for these foci, measured with the higher resolution
Zeiss Axiovert 200 microscope, is in the order of 3 mm in length
(for elongated foci in Q35) and ,7 mm
2 in area (for round foci),
with the microscopy tools and fluorescence exposure utilized in the
genetic screen (Leica MZ16FA). Data collected from different
experiments was compiled to calculate aggregate number averages
relative to the control in EV RNAi. Fluorescent microscopy
images were taken using an Axiovert 200 microscope with a
Hamamatsu digital camera C4742-98 (Carl Zeiss, Germany). All
assays were performed blind as to the identity of the RNAi by
attributing to each modifier a number corresponding to a well with
the dsRNA bacterial stock, in a 96-well plate.
Fluorescence Recovery after Photobleaching Analysis
To examine the biophysical properties of polyQ protein,
animals were subjected to FRAP analysis. Animals were mounted
on a 3% (w/v) agar pad on a glass slide and immobilized in 2 mM
levamisole. FRAP was measured using the Zeiss LSM510 confocal
microscope (Carl Zeiss, Germany), and the 636objective lens at
56zoom power, with the 514 nm line for excitation. An area of
0.623 mm
2 was bleached for 35 iterations at 100% transmission,
after which time an image was collected every 123.35 ms. Relative
fluorescence intensity (RFI) was determined as previously
described [43,75].
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For SDS-PAGE analysis, 6 day old animals grown on RNAi-
seeded NGM plates were collected and resuspended in PELE
buffer [20 mM Tris pH7.4, 10% glycerol, 2% Triton X-100,
0.5 mM PMSF, 1 mg/ml leupeptin, 1 mg/ml pepstatin, 1 mM
EDTA, 1 mM DTT, protease inhibitor cocktail tablet (Roche
Diagnostics #11836170001)]. Lysis of ,100 animals was
accomplished by a combination of 4 cycles of freeze-thaw,
grinding with a motorized pestle (Kontes #749541-000 and
#749520-0000), followed by 8 min sonication (Sonicator Bath
Branson 1510, Branson). To dissolve the polyQ aggregates, SDS
was added to a final concentration of 5.5% (v/v) and samples were
boiled for a total of 10 min. Total protein concentration was
determined using the Bradford assay (Bio-Rad #500-0006). 15 mg
(for Q35) or 20 mg (for SOD1) of total protein, in the linear range
for YFP detection [43], were analyzed on a 10% SDS-PAGE
followed by Western blotting. For YFP (polyQ and SOD1)
detection, blots were probed with the anti-GFP IR800 conjugated
antibody (1:5,000 dilution; Rockland Immunochemicals #600-
132-215). For a-tubulin detection, blots were probed with the anti-
a-tubulin primary antibody (1;4,000 dilution; Sigma #T-5168)
followed by the secondary antibody Alexa Fluor 680 goat anti-
mouse IgG (1:10,000 dilution; Molecular probes #A-21057).
Antibody binding was detected with the Odyssey Infrared Imaging
System (LI-COR Biosciences, USA). The ratio between band
intensities YFP/a-tubulin was calculated for each sample (Adobe
Photoshop 7.0, arbitrary units) and compared to the EV control
(relative %). A representative group of modifiers was tested (3
biological replicates). Statistically significant changes in protein
amounts were considered if p,0.05 (Student’s T-test).
For native PAGE analysis, animals (,100) were collected with
M9 buffer and resuspended in native-lysis buffer [50 mM Tris
pH7.4, 5 mM MgCl2, 0.5% Triton X-100, 0.2 mM PMSF, 1 mg/
ml leupeptin, protease inhibitor cocktail tablet (Roche Diagnostics
#11836170001)]. Lysis was achieved with 4 cycles of freeze-thaw,
and homogenization by grinding with the motorized pestle, always
maintaining the tubes on ice. Total protein concentration was
determined as before and 40 mg were analyzed on a 5% native
PAGE (at 4uC), followed by gel scan (STORM 860, #91393, GE
Healthcare, UK). This experiment was done in triplicate.
Motility Assays
Animals (6 days old) grown on RNAi NGM plates at 20uC were
picked (20–25 animals) onto the center of a NGM OP50-seeded
plate (full surface area covered with OP50), equilibrated at 20uC.
Animals’ movements were digitally recorded using a Leica M205
FA microscope with a Hamamatsu digital camera C10600-10B
(Orca-R2, Leica Microsystems, Switzerland), and the Hamamatsu
Simple PCI Imaging software. Videos of 45 s were recorded at
262 binning and 5 frames per second, and captured frames were
merged into *.avi format and imported directly into ImageJ. Using
the LOCI bio-formats plugin and a custom stack de-flicker plugin
(http://www.loci.wisc.edu/bio-formats/imagej), light average in-
tensity was normalized for each frame. To enhance the definition
of the animals in the movies, the difference between each frame
and the constant background was calculated, using the ‘Maximum
Z-stack’ projection. The resulting movie was converted to binary
format using Otsu Thresholding 2. Binary objects representing the
animals were tracked using custom ImageJ plugin, wrMTrck
(based on ‘‘MTrack2’’ by Nico Stuurman [76]). The average speed
of each animal was calculated by dividing the length of each track
(corrected for animal body length) by the duration of the track
(body length per second, or BLPS). The wrMTrck plugin and
scripts for automated analysis are open-source and publicly
available at http://www.phage.dk/plugins. Videos were recorded
for a minimum of 75 animals per experiment (n$3) and motility
measurements are given as a percentage of wt motility (% wt in
EV RNAi). RNAi modifiers that affected the motility of wt animals
were removed from further analysis. All motility assays were also
performed blind as to the identity of the RNAi gene-target.
Measurements of motility were validated by other read-outs that
included manual-based motility assays [10,77]. The first manual
assay measured how fast it took animals placed in the center of a
ring (circumference only) of OP50 bacteria to reach the food, and
the second manual assay monitored the number of worms that
traveled 1 cm in 1 minute on OP50 bacteria-seeded NGM plates.
All results shown were obtained with the automated worm tracker,
which provides reproducible and unbiased results.
Assay for TS Phenotypes
Temperature sensitive (TS) mutant animals were age-synchro-
nized to L1 stage by NaOCl bleaching, grown on RNAi-seeded
NGM plates (15–20 animals per plate) from day 1 at a sensitized
temperature of 23uC (to maintain the RNAi suppressor effect on
aggregation, which was used as a control) and scored for
phenotypes on day 5. For the 25uC restrictive temperature control
experiment, L1 nematodes were grown on EV RNAi at 15uC until
L4 stage to avoid embryonic and developmental phenotypes, then
transferred to 25uC and scored 2 days later for the same
phenotypes. For the 15uC permissive temperature control
experiment, animals were synchronized to L1, added to EV
RNAi plates, grown at 15uC and scored for phenotypes on day 6
(to account for slower but normal development at this tempera-
ture). At least 50 animals were scored for each specific phenotype,
per experiment (n=3), as described previously [10,42,43], and all
assays were performed blind. For the slow movement/paralysis
assay [unc-15(e1402) and unc-54(e1157)], 15–20 animals were
placed on a OP50-NGM plate at room temperature in the center
of a 1 cm circle (drawn on the bottom of the plate). Animals
remaining in the 1 cm circle after 5 min were considered to
possess a slow movement or paralyzed phenotype. To score for stiff
paralysis [unc-52(e669su250)], partially paralyzed animals with
moving heads and stick-like bodies were scored. For the egg-laying
phenotype [unc-45(e286)] partially paralyzed animals with a large
belly of accumulated eggs were scored.
Real-Time qPCR
Wt animals (5 days old and ,50) were collected from RNAi-
NGM plates and RNA was extracted with the Trizol reagent
(Invitrogen), followed by DNase treatment (Applied Biosystems
#AM1906). mRNA was then reverse transcribed using the iScript
cDNA Synthesis Kit (Bio-Rad #170-8891). 10 ng of cDNA were
used for real-time PCR amplification using the iQ SYBR Green
Supermix (Bio-Rad #170-8880) and the iCycler system (Bio-Rad)
(see Text S1). The relative expression levels of each gene were
determined using the Comparative CT Method (Real-Time PCR
Applications Guide, Bio-Rad). Gene expression levels were
normalized relative to actin (act-1) in the same sample (internal
control), and then relative to the levels of the same gene in EV
control sample. Measurements were performed for $3 biological
samples for each condition.
Supporting Information
Figure S1 C. elegans models of polyQ and human SOD1
aggregation. (A) Q35 and Q37 body sections show distinct
morphology of aggregates (white arrows) in 6 and 5 day old
animals, respectively. Scale bar is 0.1 mm. (B) Time dependent
Genetic Modifiers of the Proteostasis Network
PLoS Genetics | www.plosgenetics.org 13 December 2011 | Volume 7 | Issue 12 | e1002438aggregate count for Q35 and Q37 animals (6SD, n.3). (C) SDS-
PAGE and western blot analysis of protein samples from animals
(6 days old) expressing polyQ-YFP protein, immunoblotted with
anti-YFP (top) and anti-a-tubulin (bottom) antibodies. By standard
protein extraction, Q35 and Q37 aggregates are SDS-insoluble
and are trapped in the loading well. YFP/tubulin ratios were
calculated from protein band intensities (total YFP) and are shown
relative to Q0 (6SD). (D) Motility measurements (in body length
per second/BLPS) of 6 day old wt and polyQ animals show that
Q35 and Q37 aggregation in BWM cells causes a motility defect
(6SEM, n=3, Student t-test ***p,0.001). (E,F) Expression of
human SOD1-YFP in muscle cells: while SOD1
wt adopts a diffuse
soluble fluorescent pattern (E: II and III are zoom in of the boxed
areas on I), mutant SOD1
G93A displays a pattern of small foci (F: II
and III are zoom in of the boxed areas on I). Scale bar is 0.1 mm.
(TIF)
Figure S2 PolyQ mRNA levels in RNAi treated animals. q35-yfp
mRNA levels from RNAi-treated animals (6 days old) analyzed by
reverse transcriptase PCR amplification (top). Control corresponds
to EV and yfp-RNAi is the positive control for reduced q35-yfp
mRNA levels. Actin mRNA (bottom) is the control for total
mRNA levels. Ratio q35-yfp/actin are calculated from band
intensities, and averaged from 3 biological replicates. Student t-
test p.0.05 for all but yfp (***p,0.001).
(TIF)
Figure S3 Gene modifiers of aggregation distribution into
functional classes. (A) C. elegans genes represented in the RNAi
library (16,757). (B) RNAi suppressors of Q35 aggregation (151).
(C) Common aggregation suppressors for polyQ and SOD1
G93A
(63). Statistical significance calculated by the Chi-square test
***p,0.001.
(TIF)
Table S1 Exhaustive list and description of all RNAi targeted
genes that suppressed Q35 aggregation.
(XLS)
Table S2 Motility assays results for each modifier tested, per
assay executed, for wt and Q35 animals.
(XLS)
Table S3 Comparative analysis between genetic screens, and
overlapping gene modifiers.
(DOC)
Text S1 Supporting Information: Materials and Methods.
(DOC)
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